The ACG’s treatment guidelines for Crohn disease offer significant lessons for physicians. David A. Schwartz, MD, provided an overview at the Advances in Inflammatory Bowel Disease virtual regional meeting...
Biosimilars show promise in reducing costs and equaling efficacy, compared with originator compounds. But will they live up to that potential? Russell Cohen, MD, addressed these issues and more at the...
What exactly is precision medicine, and is it ready to be applied in gastroenterology practice? Millie Long, MD, discussed the topic at the virtual Advances in Inflammatory Bowel Disease regional meeting on...
Applying a systematic treat-to-target approach is effective for reducing the risk of long-term complications in patients with IBD, but incremental benefit must be evaluated. Siddarth Singh, MD, spoke about...
In her session, Millie Long, MD, reviewed the role of anticytokine therapy for treating Crohn disease and how new approaches to diagnosing, monitoring, and treating Crohn disease have helped advance the...
Do age, gender, development, and other characteristics in children with autism affect their likelihood of gastrointestinal symptoms? Researchers report their findings.
Triple therapy has been the gold standard for treatment of H pylori infection for several years. New research casts light on whether that standard should change.
The many different classes of medications available for treating inflammatory bowel disease give gastroenterologists more options than ever before—and also more challenges in determining how to balance...
The treatment of inflammatory bowel disease has changed dramatically since the introduction of biologics and small molecule therapeutics. But does that mean older therapies no longer have any role? David...
